Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
28 June 2017Website:
http://www.mersana.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 30 Sep 2024 20:29:49 GMTDividend
Analysts recommendations
Institutional Ownership
MRSN Latest News
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.47 per share a year ago.
CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2024.
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:
Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.44 per share a year ago.
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:
Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with substantial catalysts and make a fortune.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
What type of business is Mersana Therapeutics?
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
What sector is Mersana Therapeutics in?
Mersana Therapeutics is in the Healthcare sector
What industry is Mersana Therapeutics in?
Mersana Therapeutics is in the Biotechnology industry
What country is Mersana Therapeutics from?
Mersana Therapeutics is headquartered in United States
When did Mersana Therapeutics go public?
Mersana Therapeutics initial public offering (IPO) was on 28 June 2017
What is Mersana Therapeutics website?
https://www.mersana.com
Is Mersana Therapeutics in the S&P 500?
No, Mersana Therapeutics is not included in the S&P 500 index
Is Mersana Therapeutics in the NASDAQ 100?
No, Mersana Therapeutics is not included in the NASDAQ 100 index
Is Mersana Therapeutics in the Dow Jones?
No, Mersana Therapeutics is not included in the Dow Jones index
When was Mersana Therapeutics the previous earnings report?
No data
When does Mersana Therapeutics earnings report?
The next expected earnings date for Mersana Therapeutics is 07 November 2024